162. Pemphigoid Clinical trials / Disease details
Clinical trials : 83 / Drugs : 128 - (DrugBank : 51) / Drug target genes : 33 - Drug target pathways : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04776694 (ClinicalTrials.gov) | March 29, 2021 | 25/2/2021 | Compassionate Use of Dupilumab | Bullous Pemphigoid;Eosinophilic Esophagitis (EoE);Pediatric Asthma;Pediatric and Adolescent Chronic Rhinosinusitis With Nasal Polyps (CRSwNP);Pediatric Atopic Dermatitis | Drug: Dupilumab | Regeneron Pharmaceuticals | NULL | Available | NULL | ||||||
| 2 | NCT04206553 (ClinicalTrials.gov) | October 28, 2020 | 18/12/2019 | A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid | Bullous Pemphigoid | Drug: dupilumab;Drug: Matching Placebo;Drug: Oral corticosteroids (OCS) | Regeneron Pharmaceuticals | Sanofi | Recruiting | 18 Years | 90 Years | All | 98 | Phase 2/Phase 3 | United States;Australia;France;Germany;Japan |
| 3 | EUCTR2019-003520-20-DE (EUCTR) | 15/10/2020 | 26/03/2020 | A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid - LIBERTY-BP ADEPT | Bullous pemphigoid (BP) MedDRA version: 20.0;Level: PT;Classification code 10034277;Term: Pemphigoid;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Dupixent Product Name: dupilumab INN or Proposed INN: dupilumab Other descriptive name: DUPILUMAB | Regeneron Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 98 | Phase 2;Phase 3 | United States;France;Australia;Japan;Germany | ||
| 4 | EUCTR2019-003520-20-FR (EUCTR) | 19/05/2020 | 25/03/2020 | A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid - LIBERTY-BP ADEPT | Bullous pemphigoid (BP) MedDRA version: 20.0;Level: PT;Classification code 10034277;Term: Pemphigoid;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Dupixent Product Name: dupilumab INN or Proposed INN: dupilumab Other descriptive name: DUPILUMAB | Regeneron Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 80 | Phase 2;Phase 3 | United States;France;Spain;Australia;Germany;Japan |